doi: 10.1136/bmj.f4386.
Novo Nordisk replies to BMJ investigation on incretins and pancreatic damage
- PMID: 23842435
- DOI: 10.1136/bmj.f4386
Item in Clipboard
Novo Nordisk replies to BMJ investigation on incretins and pancreatic damage
BMJ.
.
No abstract available
Similar articles
-
Q: Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis?Cleve Clin J Med. 2010 Aug;77(8):503-5. doi: 10.3949/ccjm.77a.09167. Cleve Clin J Med. 2010. PMID: 20682512 No abstract available.
-
Incretin therapy and its effect on body weight in patients with diabetes.Prim Care Diabetes. 2012 Oct;6(3):187-91. doi: 10.1016/j.pcd.2012.04.006. Epub 2012 May 19. Prim Care Diabetes. 2012. PMID: 22613745 Review.
-
The safety of incretin based drugs.BMJ. 2014 Apr 24;348:g2779. doi: 10.1136/bmj.g2779. BMJ. 2014. PMID: 24764568 No abstract available.
-
Hyperplasia from GLP-1 drugs is "not a surprise," say researchers.BMJ. 2013 Mar 27;346:f2025. doi: 10.1136/bmj.f2025. BMJ. 2013. PMID: 23535260 No abstract available.
-
Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes.Expert Opin Biol Ther. 2010 May;10(5):801-6. doi: 10.1517/14712598.2010.481281. Expert Opin Biol Ther. 2010. PMID: 20367248 Review.
Cited by
-
Targeting orphan G protein-coupled receptors for the treatment of diabetes and its complications: C-peptide and GPR146.J Intern Med. 2017 Jan;281(1):25-40. doi: 10.1111/joim.12528. Epub 2016 Jun 16. J Intern Med. 2017. PMID: 27306986 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
